30th July 2012
Finance Wales invest Thousands in Innovative Life Science Companies
The technology ventures team at MediWales members Finance Wales are proud to announce significant investment in innovative technology businesses to accelerate their commercialisation plans:
Q Chip: £117,000
Q Chip is a biotechnology company with a strong focus on drug delivery, designed to improve patient compliance and experience through the development of long acting injectable therapeutics.
Producing uniform microspheres with high API (Active Pharmaceutical Ingredient) loading and controllable release profiles with minimal burst, Q Chip’s proprietary platform Q-SpheraTM is a breakthrough microsphere manufacturing and formulation system, compatible with small molecules, peptides and proteins.
Clinithink: £1,250,000
Founded by physicians with 20 years’ combined experience in healthcare IT and Electronic Medical Record (EMR) systems, Clinithink have built the technology that enables healthcare organizations to adequately analyze and utilize electronic medical data.
Clinithink have developed innovative technology to intelligently index and structure medical data. By integrating Clinithink’s technology into existing EMR/EHR solutions, the healthcare community is able to better understand and improve performance related to decision making, operational efficiency, outcomes, and revenue.
Finance Wales’s investment will fund its technology and will help establish its UK-based R&D function in South Wales.
Diurnal: £86,000
Diurnal is an innovative pharmaceutical, venture capital backed company that creates high-value hormone therapeutics using proprietary formulations and novel physiological treatment regimes of approved drugs.
Combining their expertise in endocrinology and drug delivery, Diurnal have created unique product opportunities in areas of high unmet medical need such as adrenal insufficiency, rheumatoid arthritis, hypogonadism and hypothyroidism.
Diurnal’s lead product Chronocort® helps patients with deficiency in the hormone cortisol. Following successful clinical trials in human volunteers, this latest investment will enable Diurnal to undertake trials in patients.